Eli Lilly and Co / LLY

Equity | Generated Aug 31, 2026 11:31 PM EDT

Current price	Daily move	Bid / Ask	Previous close
$1,158.00	**-16.61 -1.41%**	**$1,157.30/$1,165.00**	**$1,174.61**

Market	**NYSE**
Industry	**Pharmaceuticals**
Market data as of	**Aug 31, 2026 11:31 PM EDT**

JW Intelligence Report

Complete | 3 of 3 sections | Aug 31, 2026 6:50 PM EDT

JW Rank	Rank label	Confidence	IV percentile
56.9 / 100	**Balanced**	**high**	**19 / 100**

Model reference	Upside scenario	Risk reference	Wheel strategy fit
$1,150.00	**$1,220.00**	**$1,100.00**	**56 / 100**

Options stance	**bullish**
Tail-risk safety	**32 / 100**
JW Rank data coverage / as of	**100.0% | Aug 31, 2026 6:50 PM EDT**

Key insight

Lilly Option Market Implies Continued Growth and Upside Potential

Market read

The US options market for Lilly (LLY) suggests a bullish outlook, driven by strong recent earnings, pipeline advancements, and positive news flow. Despite a slight dip following the Merida Biosciences acquisition, implied volatility remains elevated, indicating anticipation of continued price movement. The term structure is in backwardation, with near-term options more expensive than those further out, suggesting a belief that LLY's growth will continue to accelerate.

Strategy context

The options market suggests a bullish outlook for LLY, driven by strong fundamentals and positive news flow. However, investors should be aware of the high valuation and potential risks associated with the Merida acquisition.

JW AI conclusions

Short- and medium-term model interpretation

AI context bias	**Bullish**
AI analysis updated	**Aug 31, 2026 1:43 PM EDT**

Short-term scenario

Cautious/speculative buy on the current dip for a 1-3 week bounce, supported by short-term oversold technicals, strong Q2 beat/raised guidance, and positive pipeline/news flow; however, high uncertainty from M&A reaction, elevated valuation, mixed indicators, and potential volatility. Not a high-conviction setup.

Three-month outlook

Constructive/bullish bias driven by GLP-1 franchise momentum (Mounjaro, Zepbound, oral Foundayo launch, retatrutide advancing toward 2027 filings), raised 2026 guidance, CV indication expansion, and pipeline diversification via deals. Analyst targets cluster around $1,300+ with 12-month upside. However, clearly identify uncertainty: high trailing P/E (~39x) leaves limited margin for error if growth decelerates or competition intensifies; acquisition integration and early-stage assets add execution risk; broader market/sector rotation, regulatory, or reimbursement variables could pressure the stock. Pullbacks remain possible before any sustained move higher.

Market sentiment

Recent posts (Aug 31) mixed-to-cautious: stock noted edging lower on Merida acquisition (viewed as early-stage, not near-term catalyst) alongside positive Taltz/Zepbound data. Praise for execution, GLP-1 dominance, and pipeline vs. peers like NVO; some highlight oversold short-term setups with historical bounce stats (e.g., median +6% in 10 days). Persistent skepticism on high valuation, institutional ownership, and competition. Overall cautious-positive on long-term fundamentals but reactive to today's news and pullback.

Supporting evidence

Implied volatility for LLY is currently 31.41%, indicating market expectations of significant price movement in the coming weeks. | The term structure is in backwardation, with near-term options more expensive than those further out, suggesting a belief that LLY's growth will continue to accelerate. | Recent positive news includes FDA approval for Mounjaro to reduce cardiovascular risk in type 2 diabetes patients and strong Q2 earnings results. | The market is also optimistic about LLY's pipeline, with advancements in Alzheimer's treatment and the potential for retatrutide filings in 2027.

Risk watch

High valuation: LLY's trailing P/E ratio is currently around 39x, which could make it vulnerable to a pullback if growth slows.

Enhanced price structure

45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor

JW RANK FACTOR PROFILE	COVERAGE	SCORE (0–100)
Liquidity	100.0%	94.0
Strategy Fit	100.0%	56.3
Technical Trend	100.0%	53.0
Market Tail Risk	100.0%	32.0
Fundamental Quality	100.0%	84.2
Volatility Pressure	100.0%	40.0

Decision summary

Primary model reads before the detailed indicator appendix

Momentum	Institutional flow	Structure	Volatility
bullish_recovery	**Below MVWAP**	**Above 200D trend**	**medium**

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	**BULLISH RECOVERY | neutral | MACD decelerating**
Trend signal	**BULLISH RECOVERY**
RSI signal	**neutral**
RSI (7 / 14 / 21)	**31.64 / 42.65 / 46.65**
RSI velocity	**-1.69**
MACD line / signal / histogram	**2.79 / - / 11.68**
MACD acceleration	**-4.42**
Stochastic K / D	**8.48 / 16.89**

Institutional footprints

Volume-weighted cost, price location and flow

Current read	**Below institutional MVWAP | Accumulation bias**
Institutional flow	**1.70**
20-day MVWAP	**$1,201.87**
Price vs 20-day MVWAP	**-3.65%**
Daily reference VWAP	**$1,158.39**
Price vs daily reference	**-0.03%**
Volume	**1.29M**

Structural context

Long-term trend and volatility boundaries

Current read	**Above 200-day trend | Positive macro velocity**
Macro velocity	**1.37**
20-day / 200-day SMA	**$1,204.30 / $1,060.62**
Bollinger range	**$1,126.13 - $1,282.47**
Bollinger position	**0.196**

Options and volatility intelligence

Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
25 / 100	**23 / 100**	**87.56**	**144.05**

Market regime	**DANGER ZONE**
Tail-risk regime	**NORMAL TAIL RISK**
Term structure	**backwardation**
Term slope	**-2.40 pts**
Skew read	**balanced**
Liquidity / quote coverage	**100.0%**
Options observation	**Aug 31, 2026 4:33 PM EDT | Coverage 88.9%**

Option term structure

ATM implied-volatility curve by days to expiration



EXPIRATION	DTE	ATM IV	STATE
2026-09-04	4	32.9%	-
2026-09-11	11	30.4%	-
2026-09-18	18	30.5%	-

Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

Bull Put Spread reference

Short $1,130.00 | Long $1,125.00 | Width $5.00 | Net credit $1.28



Max profit $128.00 | Max loss -$372.00 | Break-even $1,128.72 | Per contract at expiry

Bear Call Spread reference

Short $1,182.50 | Long $1,185.00 | Width $2.50 | Net credit $0.65



Max profit $65.00 | Max loss -$185.00 | Break-even $1,183.15 | Per contract at expiry

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	**2026-10-29**
Earnings IV-crush risk	**NOT MEASURED**
VIX	**15.17**
VVIX	**87.56**
SKEW index	**144.05**
Observation confidence	**high**
Option quote quality	**reliable**
Contracts observed	**105**

Event and tail-risk context (continued)

Known event windows and broad volatility conditions

FIELD	VALUE
Contracts with quotes	**105**

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The US options market for Lilly (LLY) suggests a bullish outlook, driven by strong recent earnings, pipeline advancements, and positive news flow. Despite a slight dip following the Merida Biosciences acquisition, implied volatility remains elevated, indicating anticipation of continued price movement. The term structure is in backwardation, with near-term options more expensive than those further out, suggesting a belief that LLY's growth will continue to accelerate.

Options context

Lilly Option Market Implies Continued Growth and Upside Potential

Wheel context

The options market suggests a bullish outlook for LLY, driven by strong fundamentals and positive news flow. However, investors should be aware of the high valuation and potential risks associated with the Merida acquisition.

Observed evidence

Implied volatility for LLY is currently 31.41%, indicating market expectations of significant price movement in the coming weeks. | The term structure is in backwardation, with near-term options more expensive than those further out, suggesting a belief that LLY's growth will continue to accelerate. | Recent positive news includes FDA approval for Mounjaro to reduce cardiovascular risk in type 2 diabetes patients and strong Q2 earnings results. | The market is also optimistic about LLY's pipeline, with advancements in Alzheimer's treatment and the potential for retatrutide filings in 2027.

Principal risks to monitor

High valuation: LLY's trailing P/E ratio is currently around 39x, which could make it vulnerable to a pullback if growth slows.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization **$1.10T**	P/E (TTM) **43.17**
ROE **92.6%**	Revenue growth **31.7%**
EPS growth **49.3%**	Operating margin **42.2%**
Net profit margin **33.5%**	Gross margin **-**
Free cash flow CAGR **5.9%**	Debt / equity **1.60**
Dividend yield **0.8%**	Beta **0.45**
52-week range **$712.05 - $1,292.65**	

Company or fund profile

Issuer identity and classification

Name **Eli Lilly and Co**	Market **NYSE**
Industry **Pharmaceuticals**	Country **US**
Currency **USD**	IPO date **1970-07-09**
Shares outstanding **941.74M**	52-week return **60.5%**
Book value per share **$35.98**	Revenue per share **$89.14**

Website	**lilly.com**

Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal

Aug 31, 2026 3:13 PM EDT

Covered Call | 2026-09-11

At signal $1,156.18 | Current $1,158.00

SHORT **Option $1,160.00 B $21.70 / A $24.60**

High turnover | CR $23.15

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	**$37.69**
ATR as % of price	**3.3%**
Volatility environment	**medium**
Current IV	**30.8%**
IV rank	**22 / 100**
IV percentile	**19 / 100**

Technical health and risk radar

Derived indicator health and event context

Overall health	**73 / 100**
Trend health	**78 / 100**
Momentum health	**78 / 100**
Volatility health	**61 / 100**
Structure health	**70 / 100**
Earnings risk / date	**low | 2026-10-29**
Macro risk	**unknown**
Volatility risk	**medium**
Structure risk	**low**

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	**$1,204.30 / $1,188.00 / $1,060.62**
EMA (9 / 21)	**$1,196.28 / $1,199.59**
Bollinger upper / middle / lower	**$1,282.47 / $1,204.30 / $1,126.13**
Bollinger %B	**0.196**
True high / low	**$1,174.61 / $1,147.00**

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
5-day true high / low	**$1,264.73 / $1,147.00**

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	1.371	**-**
SMA50	1.163	**-**
MVWAP20	1.703	**-**
MACD	-4.422	**-**
RSI	-1.687	**-**
Volume	-159860.000	**-**
ATR	-1.363	**-**
T1	-	**7.39 / 1199.95 / 1180.00 / 1162.93**
T2	-	**11.34 / 1197.87 / 1190.11 / 1171.71**
T3	-	**16.06 / 1196.77 / 1235.78 / 1180.01**

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	**$1,154.19**
Options intelligence as of	**Aug 31, 2026 4:33 PM EDT**
Options data coverage	**88.9%**
SKEW regime	**HIGH TAIL RISK SKEW**
VVIX regime	**VVIX FLAT**
Front expiration / DTE	**2026-09-04 | 4 DTE**
Front at-the-money IV	**32.9%**
25-delta skew	**-0.03**
Put / Call 25-delta	**$1,130.00 Delta -0.262 / $1,182.50 Delta 0.258**
Median option bid/ask spread	**19.0%**
Bid/ask spread	**-**
Contracts observed / quoted	**105 / 105**

Price context

Last Price: 1,154.19 | Bid: 1,154.00 | Ask: 1,154.39 | Previous Close: 1,174.61 | Change: -20.42 | Daily change: -1.74% | Update Time: 2026-08-31T14:44:21.585023-04:00 | Latest History Date: 2026-08-31 | Latest History Price: 1,154.19

Historical context

Trading-day sample: 60 sessions | First Date: 2026-06-05 | Latest Date: 2026-08-31 | Latest Price: 1,154.19 | Max Drawdown 60d Percent: -9.85%

Fundamental context

Current Iv Percent: 31.41% | Iv Rank: 24.58 | Iv Percentile: 22.71 | Next Earnings Date: 2026-10-29 | Ex Dividend Date: 2026-08-13 | Dividend Yield: 59.00

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	**jasonwheel.com**
Terms of Use	**jasonwheel.com / Terms**
Privacy Policy	**jasonwheel.com / Privacy**
Options Disclosure Document	**theocc.com / Options Disclosure Document**